Effects and Time-Kill Assessment of Amoxicillin Used in Combination with Chloramphenicol Against Bacteria of Clinical Importance Olufunmiso O

Total Page:16

File Type:pdf, Size:1020Kb

Effects and Time-Kill Assessment of Amoxicillin Used in Combination with Chloramphenicol Against Bacteria of Clinical Importance Olufunmiso O Vol. 64, No 4/2017 609–613 https://doi.org/10.18388/abp.2016_1495 Regular paper Effects and time-kill assessment of amoxicillin used in combination with chloramphenicol against bacteria of clinical importance Olufunmiso O. Olajuyigbe1,2*, Roger M. Coopoosamy1 and Anthony J. Afolayan2 1Department of Nature Conservation, Mangosuthu University of Technology, Durban, KwaZulu-Natal, South Africa; 2Medicinal Plants and Eco- nomic Development Research Centre, University of Fort Hare, Alice, 5700, South Africa With the emergence of multidrug-resistant organisms in INTRODUCTION an era when drug development faces challenges caus- ing pharmaceutical companies to curtail or abandon In the late twentieth century the availability and suc- research on anti-infective agents, the use of combined cess of antibiotics and vaccinations resulted in a confi- existing antimicrobial agents may be an alternative. dence that technology and modern medicine would be This study evaluated the effects of combining amoxicil- victorious against infectious diseases. During this early lin and chloramphenicol, to which many bacteria have period of the antibiotic usage bacterial infections were become resistant, in vitro against Gram positive and considered tamed as potentially lethal infections were be- Gram negative bacteria by agar diffusion, checkerboard ing cured with antibiotics. However, while the introduc- and time-kill assays. The test isolates were susceptible tion of antimicrobial agents was accompanied by nega- to amoxicillin with minimum inhibitory concentrations tive rather than positive impact on the patients, the num- (MICs) ranging between 0.448 and 500 µg/ml and be- ber of individuals to be treated with antibiotics increased tween 1.953 and 31.25 µg/ml for chloramphenicol. Upon with enhanced pathogenicity and invasiveness. The wide- combining these agents, there was a drastic reduction spread use of antibiotic, therefore, resulted in the emer- in their MICs indicating an increased antibacterial activ- gence of outbreaks and epidemics of antibiotic-resistant ity that showed synergistic interaction against all the pathogens including multidrug resistant strains (Normak bacteria. At the highest concentrations, the inhibition & Normak, 2002). Today, resistant pathogens, an under- zones ranges were 20.33–38.33±0.58 µg/ml for amoxi- appreciated threat to public health throughout the globe cillin, 27.67–37.67±0.58 µg/ml for chloramphenicol and (Zhang et al., 2006), are rapidly growing problems lead- 31.67–39.33±0.58 µg/ml for the combined agents. The ing to an urgent need for novel antimicrobial agents fractional inhibitory concentration indices (FICIs) showed (Kumar & Schweizer, 2005; Edgar et al., 2012). synergy ranging from 0.129 to 0.312 while FICIs for ad- Although there is a continued effort into seeking new ditive interaction were between 0.688 and 1.0. There therapies in response to the consequences of the pres- 1 was no antagonistic interaction. At the /2MICs of the sure on the widespread use of antibiotics or problems combined antibiotics, all the tested bacteria, except for associated with increasing drug resistance (Cameron et Klebsiella pneumoniae ATCC 4352, Proteus vulgaris CSIR al., 2004), bacteria have, also, continued to develop dif- 0030 and Enterococcus cloacae ATCC 13047 were elimi- ferent resistance mechanisms to virtually all antibiotics in nated before 24 h. At the MICs, all the tested bacteria general clinical practices (Clatworthy et al., 2007). These were eliminated except Enterococcus cloacae ATCC 13047 resistance mechanisms may include altered penicillin- which was almost totally eliminated. Post-antibiotic as- binding proteins, presence of various β-lactamases and sessment after 48 h showed that all the cultures were loss of porins (Bou & Martïnez-Beltran, 2000). While sterile except for that of Enterococcus cloacae ATCC active efflux and enzymatic inactivation are the mecha- 13047. The lack of antagonism between these antibacte- nisms responsible for resistance to aminoglycosides rial agents in checkerboard and time-kill assays suggest- (Smith et al., 2007), the most common mechanisms of ed that combining amoxicillin with chloramphenicol can resistance to chloramphenicol are decreased outer mem- provide an improved therapy in comparison to the use brane permeability (Burns et al., 1989), enzymatic inac- of each antibiotic individually. The study indicates the tivation by acetylation essentially by acetyltransferase or potential beneficial value of combining amoxicillin and by chloramphenicol phosphotransferases (Schwartz et al., chloramphenicol in the treatment of microbial infections 2004; Aakra et al., 2010), target site modulation (Montero in clinical settings. et al., 2007) and presence of efflux pump (Daniels & Ra- mos, 2009). To overcome various resistance mechanisms Keywords: drug-drug interactions; fractional inhibitory concentra- and dissemination of antibiotic resistance genes, explor- tions; multidrug resistance; time-kill assessment ing the possible synergy between conventional antibiot- Received: 31 December, 2016; revised: 13 February, 2017; accepted: ics becomes necessary. This study, therefore, aimed at 11 August, 2017; available on-line: 30 November, 2017 investigating the combinatory effects and time-kill assess- *e-mail: [email protected] ment of amoxicillin and chloramphenicol against bacteria Abbreviations: FICIs, fractional inhibitory concentration indices; of clinical importance. These antibiotics have long been MDR, multidrug resistance; MICs, minimum inhibitory concentra- used for the treatment of enteric fever. However, most tions enteric organisms including Salmonella typhi causing ty- phoid fever have become highly resistant to them (Ka- bra, 2000; Das & Bhattacharya, 2000). 610 O. O. Olajuyigbe and coworkers 2017 1 MATERIALS AND METHODS Hinton broth at /2MIC and MIC respectively. Controls consisting of Mueller Hinton broth with the respective Bacterial culture and preparation of antibiotic so- antibiotic added alone at the test concentrations were in- lutions. The bacteria used in this study included Shigella cluded in each experiment. The experimental and control sonnei ATCC 29930, Salmonella typhi ATCC 13311, Staphy- flasks were inoculated with each test organism to a final 9 lococcus aureus OK2a, Acinetobacter calcoaceuticus UP, Ente- inoculum density of approximately 10 cfu/ml. Immedi- rococcus cloacae ATCC 13047, Proteus vulgaris CSIR 0030, ately after inoculation, aliquots (100 μl) of the negative Pseudomonas aeruginosa ATCC 19582, Bacillus cereus ATCC control flasks were taken, serially diluted in sterile dis- 10702, Klebsiella pneumoniae ATCC 4352 and Staphylococcus tilled water and plated on nutrient agar in order to deter- aureus ATCC 6538. Antibiotic powders of Amoxicillin mine the zero h counts. The test flasks were incubated (Duchefa) and Chloramphenicol (Duchefa) were used. at 37°C with shaking on an orbital shaker at 120 rpm. Stock antibiotic solutions were prepared and dilutions A 100 µl aliquot was removed from the culture medium made according to the manufacturer’s recommendations. at 0, 24 and 48 h for the determination of cfu/ml. The Antibiotic susceptibility testing-Agar diffusion problem of antibiotics carryover was addressed by dilu- method. Each bacterial strain’s colony suspension was tion. After incubation, emergent bacterial colonies were matched with 0.5 McFarland standards to give a resultant enumerated, the mean count (cfu/ml) for each test and 7 concentration of 1.5×10 cfu/ml. The antibiotic suscep- controls was calculated and expressed as log10. The in- tibility was determined by swabbing the Mueller-Hinton teractions were considered synergistic if there was a de- agar (MHA) (Oxoids UK) plates with the adjusted bacte- crease of >2 log10 cfu/ml in colony counts after 24 h rial strains. Agar wells were made with heat sterilized 6 for the antibiotics combination compared to the activity mm cork borer before being filled with 100 µl of differ- of each antibiotic used alone. Additivity or indifference ent solutions (62.5 µg/ml, 125 µg/ml and 250 µg/ml) of was described as a <2 log10 cfu/ml change in the av- each of the antibiotics. These concentration ranges were erage viable counts after 24 h for the combination, in chosen to cover the maximum serum therapeutic range comparison to the activity of each antibiotic used alone. that could be reached in vivo when 100 µl of each anti- Antagonism was defined as a >2 log10 cfu/ml increase in biotic was dispensed. Different solutions containing the colony counts after 24 h for the combination compared same concentrations of amoxicillin and chloramphenicol to the activity of each antibiotic used alone (Pankey et were prepared and used to determine the effect of com- al., 2005). bining the antibiotics with care taken to prevent spillage Statistical analysis. All the data were subjected to of the solutions onto the agar surface. The plates, in one way analysis of variance (ANOVA) and the mean triplicate, were allowed to stand for 1 h before being in- values were separated at p<0.05 using Duncan’s Multiple cubated at 37°C for 24 h. After incubation, the diameter Range Test. The one way ANOVA test was used to de- of the inhibition zones produced by each antibiotic alone termine if there was any statistically significant difference and their combinations were measured with a transpar- in the size of inhibition zones for each bacterial isolate ent ruler. Synergism was stated when inhibition zones of exposed to each antibiotic
Recommended publications
  • Technical Information
    Technical Information Antibiotic Assay Medium No.1 (Seed Agar) Product Code : DM1003 Application: - Antibiotic Assay Medium No.1 (Seed Agar) is used in the microbiological assay of beta-lactam and other antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 6.000 or detecting faecal coliforms drinking in water waste water, seawater and foods samples by MPN Method. Casein enzymic hydrolysate 4.000 Yeast extract 3.000 Beef extract 1.500 Dextrose 1.000 Agar 15.000 Final pH (at 25°C) 6.6±0.2 **Formula adjusted, standardized to suit performance parameters Principle & Interpretation The potency of an antibiotic can be determined by chemical, physical and biological methods. An assay is performed to determine the ability of an antibiotic to kill or inhibit the growth of living microorganisms. Biological tests offer the most convenient m eans of performing an assay (1), since a reduction in the antimicrobial activity of a specific antibiotic reveals changes that is not usually displayed by chemical methods (2). Antibacterial susceptibility testing may be performed by either dilution (turbidimetric) or diffusion methods. The choice o f methodology is based on many factors, including ease of performance, flexibility and use of automated or semi-automated devices for both identification and susceptibility testing (3). Grove and Randall have elucidated antibiotic assays and media in their comprehensive treatise on antibiotic assays (4). Antibiotic Assay Medium No.1 is used in the microbiological assay of ß-lactam and other antibiotics. These media are prepared according to the specifications detailed in various pharmacopoeias (2-6) and by the FDA (7).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith Et Al
    USOO9662400B2 (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith et al. (45) Date of Patent: *May 30, 2017 (54) METHODS FOR PRODUCING A (2013.01); C08B 37/003 (2013.01); C08L 5/08 BODEGRADABLE CHITOSAN (2013.01); A6 IK 38/00 (2013.01); A61 L COMPOSITION AND USES THEREOF 2300/404 (2013.01) (58) Field of Classification Search (71) Applicant: University of Memphis Research CPC ...... A61K 47/36; A61K 31/00; A61K 9/7007; Foundation, Memphis, TN (US) A61K 9/0024; A61 L 15/28: A61L 27/20; A61L 27/58: A61L 31/042; C08B 37/003 (72) Inventors: James Keaton Smith, Memphis, TN USPC ................................ 514/23, 40, 777; 536/20 (US); Ashley C. Parker, Memphis, TN See application file for complete search history. (US); Jessica A. Jennings, Memphis, (56) References Cited TN (US); Benjamin T. Reves, Memphis, TN (US); Warren O. U.S. PATENT DOCUMENTS Haggard, Bartlett, TN (US) 4,895,724. A * 1/1990 Cardinal .............. A61K9/0024 424,278.1 (73) Assignee: The University of Memphis Research 5,541,233 A 7/1996 Roenigk Foundation, Memphis, TN (US) 5,958,443 A 9/1999 Viegas et al. 6,699,287 B2 3/2004 Son et al. (*) Notice: Subject to any disclaimer, the term of this 6,989,157 B2 1/2006 Gillis et al. patent is extended or adjusted under 35 7,371.403 B2 5/2008 McCarthy et al. 2003, OO15825 A1 1/2003 Sugie et al. U.S.C. 154(b) by 0 days. 2003/0206958 A1 11/2003 Cattaneo et al.
    [Show full text]
  • Antibiotic Assay Medium No. 3 (Assay Broth) Is Used for Microbiological Assay of Antibiotics. M042
    HiMedia Laboratories Technical Data Antibiotic Assay Medium No. 3 (Assay Broth) is used for M042 microbiological assay of antibiotics. Antibiotic Assay Medium No. 3 (Assay Broth) is used for microbiological assay of antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 5.000 Beef extract 1.500 Yeast extract 1.500 Dextrose 1.000 Sodium chloride 3.500 Dipotassium phosphate 3.680 Potassium dihydrogen phosphate 1.320 Final pH ( at 25°C) 7.0±0.2 **Formula adjusted, standardized to suit performance parameters Directions Suspend 17.5 grams in 1000 ml distilled water. Heat if necessary to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Advice:Recommended for the Microbiological assay of Amikacin, Bacitracin, Capreomycin, Chlortetracycline,Chloramphenicol,Cycloserine,Demeclocycline,Dihydrostreptomycin, Doxycycline, Gentamicin, Gramicidin, Kanamycin, Methacycline, Neomycin, Novobiocin, Oxytetracycline, Rolitetracycline, Streptomycin, Tetracycline, Tobramycin, Trolendomycin and Tylosin according to official methods . Principle And Interpretation Antibiotic Assay Medium is used in the performance of antibiotic assays. Grove and Randall have elucidated those antibiotic assays and media in their comprehensive treatise on antibiotic assays (1). Antibiotic Assay Medium No. 3 (Assay Broth) is used in the microbiological assay of different antibiotics in pharmaceutical and food products by the turbidimetric method. Ripperre et al reported that turbidimetric methods for determining the potency of antibiotics are inherently more accurate and more precise than agar diffusion procedures (2). Turbidimetric antibiotic assay is based on the change or inhibition of growth of a test microorganims in a liquid medium containing a uniform concentration of an antibiotic. After incubation of the test organism in the working dilutions of the antibiotics, the amount of growth is determined by measuring the light transmittance using spectrophotometer.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Application of Various Chemotherapeutic Agents in Experimental Bovine Anaplasmosis S.K
    APPLICATION OF VARIOUS CHEMOTHERAPEUTIC AGENTS IN EXPERIMENTAL BOVINE ANAPLASMOSIS S.K. Sharma, D.P. Banerjee, O.P. Gautam To cite this version: S.K. Sharma, D.P. Banerjee, O.P. Gautam. APPLICATION OF VARIOUS CHEMOTHERAPEUTIC AGENTS IN EXPERIMENTAL BOVINE ANAPLASMOSIS. Annales de Recherches Vétérinaires, INRA Editions, 1977, 8 (3), pp.307-313. hal-00900943 HAL Id: hal-00900943 https://hal.archives-ouvertes.fr/hal-00900943 Submitted on 1 Jan 1977 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. APPLICATION OF VARIOUS CHEMOTHERAPEUTIC AGENTS IN EXPERIMENTAL BOVINE ANAPLASMOSIS S.K. SHARMA, D.P. BANERJEE O.P. GAUTAM Department of Veterinary Medicine, College of Veterinary Sciences, Haryana Agricultural University, Hlssar-125004, Haryana, India ’ Résumé UTILISATION DE DIVERS AGENTS CHIMIOTHERAPEUTIQUES AU COURS DE L’ANAPLAS- MOSE BOVINE EXPERIMENTALE. &horbar; Un essai de traitement a été réalisé avec différents agents ehimiothérapeutiques, sur des cas cliniques ou des porteurs inapparents d’ana- plasmose bovine expérimentale. La Dithiosemicarbazone (associée à l’Oxytétracycline), le Chloramphénicol et la Rolitétracycline ont très efficacement entraîné la guérison clinique et l’élimination des agents pathogènes. L’imidocarb a entraîné la guérison clinique sans supprimer complètement les microorganismes.
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Of Significant in Vitro Antagonism Between Penicillin, Cephalothin, and Rolitetracycline FRANZ D
    ANTIMICROBIAL AGENTS AND CHEmoTHzRAPY, Nov. 1976, p. 802-808 Vol. 10, No. 5 Copyright © 1976 American Society for Microbiology Printed in U.S.A. Combination of Bacteriostatic and Bactericidal Drugs: Lack of Significant In Vitro Antagonism Between Penicillin, Cephalothin, and Rolitetracycline FRANZ D. DASCHNERI Children Hospital, Division ofAntimicrobial Therapy, University ofMunich, 8 Munich 2, Germany Received for publication 16 April 1976 Although it is generally believed that bactericidal and bacteriostatic drugs should not be combined in vivo, in vitro experiments using the checkerboard dilution technique revealed no antagonism between penicillin/cephalothin and rolitetracycline but rather additive or synergistic activity of either drug combi- nation in 40 to 50% of20 Escherichia coli and 14 Staphylococcus aureus strains. Slight antagonism occurred only between 3 and 8 h after combining penicillin/ cephalothin and rolitetracycline in either bacteriostatic or bactericidal concen- trations, but not after 24 h of incubation, nor was antagonism found with combinations of these drugs in bacteriostatic concentrations. Neither bacterio- static nor bactericidal activity of penicillin/cephalothin and rolitetracycline was inhibited by pretreatment of one E. coli strain with bacteriostatic rolitetracyc- line or bacteriostatic penicillin/cephalothin concentrations. Penicillin and ceph- alothin could exert a bactericidal effect after 2-h exposure of theE. coli strain to bacteriostatic rolitetracycline concentrations. Combined action of subinhibitory penicillin and rolitetracycline concentrations resulted in more pronounced inhi- bition of growth than either drug alone. The higher activity of penicillin/ cephalothin in combination with rolitetracycline on some E. coli and S. aureus strains might be due to a better access of rolitetracycline into bacterial cells whose cell walls have been weakened by cell wall-active, bactericidal drugs.
    [Show full text]
  • Characterization and in Vitro Release Studies of Tetracycline and Rolitetracycline Imobilized on Anionic Collagen Membranes
    Materials Research, Vol. 12, No. 1, 69-74, 2009 © 2009 Characterization and in vitro Release Studies of Tetracycline and Rolitetracycline Imobilized on Anionic Collagen Membranes Gilberto Goissisa*, Maria Helena de Sousab* aDepartamento de Produção, Biotech Biomédica Produtos Médicos e Odontológicos Ltda. Rua Santos Dumont, 800, Vila Celina, 13566-445 São Carlos - SP, Brazil bFaculdade Farmácia, Campus de Jatai, Universidade Federal de Goiás – UFG, Jatai - GO, Brazil Received: June 20, 2008; Revised: January 6, 2009 This work reports the covalent immobilization of tetracycline and rolitetracycline over anionic collagen membranes and the drug release studies as an effort to develop a two stage drug release based on diffusion (fast release) and on the rate of membrane biodegradation (slow release). Independent from casting conditions antibiotics incorporated by dispersion were released in the range from 80 to 100% within 7 hours in concentrations significantly higher than those described for the prevention of bacterial growth. Antibiotic release within this period was predominantly diffusion controlled. Covalent immobilization by a modified azide procedure occurred with preservation of collagen structure independently from pH of casting and reaction conditions. Its expected that anionic collagen membranes with dispersed and covalently bound rolitetracycline or tetracycline, in association with conventional therapy, may significantly reduce membrane induced infections observed post-implantation, one of the major problem associated with periodontal ligaments reconstruction by the Guided Tissue Regeneration procedure. Keywords: antibiotic, immobilization, covalent, release, collagen, membranes 1. Introduction Sustained drug release technology1 is being applied from protein this purpose formulations include tetracycline fibber, doxycycline hormones such as insulin for the treatment of diabetes2 to antibiotics polymer, chlorhexidine chip, minocycline ointment and metronida- for the prevention or minimization of bacterial infection3-5.
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • Antibiotics and Antibiotic Resistance
    This is a free sample of content from Antibiotics and Antibiotic Resistance. Click here for more information on how to buy the book. Index A Antifolates. See also specific drugs AAC(60)-Ib-cr, 185 novel compounds, 378–379 ACHN-975 overview, 373–374 clinical studies, 163–164 resistance mechanisms medicinal chemistry, 166 sulfamethoxazole, 378 structure, 162 trimethoprim, 374–378 AcrAB-TolC, 180 Apramycin, structure, 230 AcrD, 236 Arbekacin, 237–238 AdeRS, 257 Avibactam, structure, 38 AFN-1252 Azithromycin mechanism of action, 148, 153 resistance, 291, 295 resistance, 153 structure, 272 structure, 149 Aztreonam, structure, 36 AIM-1, 74 Amicoumacin A, 222 Amikacin B indications, 240 BaeSR, 257 structure, 230 BAL30072, 36 synthesis, 4 BB-78495, 162 Aminoglycosides. See also specific drugs BC-3205, 341, 344 historical perspective, 229–230 BC-7013, 341, 344 indications, 239–241 b-Lactamase. See also specific enzymes mechanism of action, 232 classification novel drugs, 237 class A, 67–71 pharmacodynamics, 238–239 class B, 69–74 pharmacokinetics, 238–239 class C, 69, 74 resistance mechanisms class D, 70, 74–77 aminoglycoside-modifying enzymes evolution of antibiotic resistance, 4 acetyltransferases, 233–235 historical perspective, 67 nucleotidyltransferases, 235 inhibitors phosphotransferases, 235 overview, 37–39 efflux-mediated resistance, 236 structures, 38 molecular epidemiology, 236–237 nomenclature, 67 overview, 17, 233 b-Lactams. See also specific classes and antibiotics ribosomal RNA modifications, 235–236 Enterococcus faecium–resistancemechanisms,
    [Show full text]
  • New Classification Framework of Tetracyclines And
    Cornell University Library Arxiv.org/quantitative-biology/biomolecules New Classification Framework and Structure-Activity- Relationship (SAR) of Tetracycline-Structure-Based Drugs Domenico Fuoco, Pharm.D., Ph.D BioTech Consultant; Member of Italian National Order of Chemists and Italian Chemical Society in Rome, Italy By studying the literature about Tetracyclines (TCs), it becomes clearly evident that TCs are very dynamic molecules. In some cases, their structure-activity-relationship (SAR) are known, especially against bacteria, while against other targets, they are virtually unknown. In other diverse yields of research, such as neurology, oncology and virology the utility and activity of the tetracyclines are being discovered and are also emerging as new technological fronts. The first aim of this paper is classify the compounds already used in therapy and prepare the schematic structure in which include the next generation of TCs. The aim of this work is introduce a new framework for the classification of old and new TCs, using a medicinal chemistry approach to the structure of that drugs. A fully documented Structure-Activity-Relationship (SAR) is presented with the analysis data of antibacterial and nonantibacterial (antifungal, antiviral and anticancer) tetracyclines. Lipophilicity of functional groups and conformations interchangeably are determining rules in biological activities of TCs. Upper peripheral modification region Introduction The number of articles published on tetracycline drugs reached the threshold of 50,000 papers since 1948. Over the last 10 years, technological fields are emerging in bacteriology and cellular physiology of eukaryotic cells. However, Lower peripheral non modifiable region chemical mechanisms of tetracyclines are not completely understood as for their action in human cells and to this day, no (Q)SAR model Figure 1.
    [Show full text]
  • Summary Report on Antimicrobials Dispensed in Public Hospitals
    Summary Report on Antimicrobials Dispensed in Public Hospitals Year 2014 - 2016 Infection Control Branch Centre for Health Protection Department of Health October 2019 (Version as at 08 October 2019) Summary Report on Antimicrobial Dispensed CONTENTS in Public Hospitals (2014 - 2016) Contents Executive Summary i 1 Introduction 1 2 Background 1 2.1 Healthcare system of Hong Kong ......................... 2 3 Data Sources and Methodology 2 3.1 Data sources .................................... 2 3.2 Methodology ................................... 3 3.3 Antimicrobial names ............................... 4 4 Results 5 4.1 Overall annual dispensed quantities and percentage changes in all HA services . 5 4.1.1 Five most dispensed antimicrobial groups in all HA services . 5 4.1.2 Ten most dispensed antimicrobials in all HA services . 6 4.2 Overall annual dispensed quantities and percentage changes in HA non-inpatient service ....................................... 8 4.2.1 Five most dispensed antimicrobial groups in HA non-inpatient service . 10 4.2.2 Ten most dispensed antimicrobials in HA non-inpatient service . 10 4.2.3 Antimicrobial dispensed in HA non-inpatient service, stratified by service type ................................ 11 4.3 Overall annual dispensed quantities and percentage changes in HA inpatient service ....................................... 12 4.3.1 Five most dispensed antimicrobial groups in HA inpatient service . 13 4.3.2 Ten most dispensed antimicrobials in HA inpatient service . 14 4.3.3 Ten most dispensed antimicrobials in HA inpatient service, stratified by specialty ................................. 15 4.4 Overall annual dispensed quantities and percentage change of locally-important broad-spectrum antimicrobials in all HA services . 16 4.4.1 Locally-important broad-spectrum antimicrobial dispensed in HA inpatient service, stratified by specialty .
    [Show full text]